ASHA 091
Alternative Names: ASHA-091Latest Information Update: 28 Feb 2025
At a glance
- Originator Asha Therapeutics
- Class Anti-infectives; Antidementias; Antiparkinsonians
- Mechanism of Action Death-associated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Ischaemic stroke; Parkinson's disease; Spinal cord injuries
Most Recent Events
- 28 Feb 2025 Preclinical trials in Spinal cord injuries in USA (unspecified route) before February 2025 (Asha Therapeutics Pipeline, February 2025)
- 08 Mar 2024 Preclinical trials in Alzheimer's disease in USA (unspecified route) prior to March 2024
- 08 Mar 2024 Pharmacodynamics data from preclinical studies in Alzheimer's disease and Parkinson disease were released by Asha Therapeutics